Latest from Hollings Cancer Center

David T. Marshall, MD, MS, professor, director, Medical Residency Program, Department of Radiation Oncology, Medical University of South Carolina, discusses the ASCENDE-RT trial, which compared dose-escalated external beam radiation therapy versus low-dose-rate brachytherapy for men with unfavorable-risk localized prostate cancer.

Carolyn D. Britten, MD, chief, Division of Hematology Oncology, associate director, Clinical Investigations, at the Hollings Cancer Center, Medical University of South Carolina, discusses questions that remain in immunotherapy.

Britten continues as Associate Director for Clinical Investigations for the MUSC Hollings Cancer Center.

International genome-­wide association study (GWAS) also identifies key gene responsible for expressing subtype of ovarian cancer.

New England Journal of Medicine Publishes Study Co-Led by Hollings Cancer Center Researcher Showing Potential of New Genomic Test In Lung Screening.

Dr. Matthew J. Carpenter, an associate professor at the Medical University of South Carolina and researcher with the MUSC Hollings Cancer Center, is the recipient of the 2015 Governor's Young Scientist Award for Excellence in Scientific Research.

Most oncologists do not regularly provide evidence-based tobacco cessation support for patients with cancer who smoke. However, addressing tobacco use is not as difficult as some might think.

Increasing the minimum age of legal access (MLA) to tobacco products will prevent or delay initiation of tobacco use by adolescents and young adults, particularly those ages 15 to 17, and improve the health of Americans across the lifespan.